


Espresso (ESP) is a high-performance Rollup platform designed to deliver a secure, fast, and seamless Layer 2 (L2) trading experience. Esteemed by major blockchain teams like Offchain Labs and Polygon, Espresso stands out with a robust infrastructure that enhances transaction efficiency across decentralized networks. By leveraging cutting-edge technology, it addresses the common blockchain scalability issues, offering users expedited transactions while reducing costs.
Espresso operates on an advanced Rollup framework that aggregates numerous transactions off the main blockchain, processes them, and then posts a summary back to the main chain. This process significantly speeds up transaction times while lowering fees. It acts as a conduit for secure interactions, maintaining transparency through cryptographic proofs that validate all on-chain activities.
Primarily, Espresso facilitates high-speed trading and direct investments on L2 platforms. Its advanced capabilities make it an appealing choice for developers and enterprises seeking scalable solutions for smart contracts and decentralized applications. Moreover, by integrating with leading blockchains, Espresso opens avenues for cross-chain compatibility, enabling users to leverage its benefits across multiple network platforms.
Purchasing Espresso (ESP) is straightforward and accessible, especially now that it's live on the WEEX Exchange. To begin trading ESP/USDT, new users should first register on WEEX, whereas existing users can log in on WEEX. After securing your account, you can proceed to trade ESP/USDT. For a direct buying experience, visit the trading platform to exchange funds.
With the support of allies, the ruling party aims to give preliminary approval to the project promoted by Federico Sturzenegger. At the beginning of the session, remote voting for senators Anabel Fernández Sagasti and Flavio Fama was ruled out. Additionally, libertarian Joaquín Benegas Lynch asserte...
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.